Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Maternal valproate dosage and foetal malformations.

F J E Vajda1, M J Eadie

  • 1Raoul Wallenberg Centre, St Vincent's Hospital, Australian Centre for Clinical Neuropharmacology, University of Melbourne, Melbourne, Australia. vajdafj@svhm.org.au

Acta Neurologica Scandinavica
|August 16, 2005
PubMed
Summary

Sodium valproate exposure during pregnancy significantly increases the risk of fetal malformations. This risk escalates with higher maternal doses, suggesting a dose-dependent teratogenic effect.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neurological factors and Cesarean section in Australian women with epilepsy.

Epilepsy & behavior : E&B·2022
Same author

Antiepileptic drugs and foetal malformation: analysis of 20 years of data in a pregnancy register.

Seizure·2018
Same author

Antiepileptic drug polytherapy in pregnant women with epilepsy.

Acta neurologica Scandinavica·2018
Same author

Predicting epileptic seizure control during pregnancy.

Epilepsy & behavior : E&B·2017
Same author

Anti-epileptic drug exposure and risk of foetal death in utero.

Acta neurologica Scandinavica·2017
Same author

Triptan use in Australia 1997-2015: A pharmacoepidemiological study.

Acta neurologica Scandinavica·2017

Area of Science:

  • Obstetrics and Gynecology
  • Pharmacology
  • Teratology

Background:

  • Antiepileptic drugs (AEDs) are commonly used during pregnancy.
  • Understanding the teratogenic potential of specific AEDs is crucial for maternal and fetal health.
  • Sodium valproate is a widely prescribed AED with suspected risks.

Purpose of the Study:

  • To investigate the dose-dependent relationship between maternal sodium valproate exposure and fetal malformation rates.
  • To compare malformation rates in pregnancies exposed to sodium valproate versus other AEDs or no AEDs.

Main Methods:

  • Analysis of data from the Australian Registry of Antiepileptic Drugs in Pregnancy.
  • Comparison of fetal malformation rates across four groups: valproate-exposed, other AED-exposed (without valproate), and no AED exposure.

Related Experiment Videos

  • Statistical analysis to determine dose-response relationships and significance.

    • Main Results:

    • Higher fetal malformation rates were observed in pregnancies exposed to sodium valproate (alone or with other AEDs) compared to those exposed to other AEDs or no AEDs.
    • A significant positive correlation was found between maternal sodium valproate dosage and fetal malformation rate.
    • Doses exceeding 1400 mg/day were associated with a steeper increase in malformation rates and altered malformation patterns.

    Conclusions:

    • Fetal exposure to sodium valproate during pregnancy poses a significant, dose-dependent risk of malformations.
    • The teratogenic mechanisms of sodium valproate may differ from those of other AEDs.
    • Risk assessment and management strategies should consider the dose of sodium valproate prescribed during pregnancy.